HER2/neu in systemic therapy for women with breast cancer: a systematic review-Reference-Cited by-同舟云学术

HER2/neu in systemic therapy for women with breast cancer: a systematic review

Published:2007-07-17 Issue:2 Volume:109 Page:209-229
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Dhesy-Thind Bindi,Pritchard Kathleen I.,Messersmith Hans,O’Malley Frances,Elavathil Leela,Trudeau Maureen

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-007-9656-y.pdf

Reference76 articles.

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

2. O’Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA (1991) The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63(3):444–446

3. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834

4. Review Manager (RevMan) [Computer Program]. Version 4.2.7 for Windows XP. Oxford: The Cochrane Collaboration, 2004. Available from: http://www.cc-ims.net/RevMan

5. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C (2001) Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19(14):3376–3384

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy;Journal for ImmunoTherapy of Cancer;2024-04

2. A careful reassessment of anthracycline use in curable breast cancer;npj Breast Cancer;2021-10-08

3. Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials;Clinical Cancer Research;2021-10-06

4. Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing;Current Medicinal Chemistry;2020-04-29

5. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required;Current Cancer Drug Targets;2018-07-31